Lupin shares hit 52-week high on strong Q2 results
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
pharmaceutical firm
November 2023
October 2022
Gland Pharma hits 52-week low; Here’s why
Over the past 10 months, the pharmaceutical firm's stock has fallen more than 58%.
